George et al. 2007
India
PEDro=3
Pre-post
N=18

Population: Age = 20-53yrs; Gender: males = 17, females = 1.
Treatment: Oxybutynin, propantheline, and capsaicin solution were instilled intravesically.  Oxybutynin and propantheline were administered 3 times daily by a double blind method with a 6 day washout period between each drug.  Patients receiving propantheline or oxybutynin had urodynamic studies done before and 3 hours after the instillation of the third dose. The capsaicin instillation was not possible to blind and urodynamic studies were repeated 1 and 2 weeks after instillation of the drug.
Outcome Measures: Reflex volume, detrusor leak point pressure, cystometric capacity, and urine leak frequency.

• Pre and post responses between intravesical oxybutynin, propantheline, and capsaicin showed significant differences at 2 weeks with respect to leak volume (p=0.017) and leak frequency (p=0.003). However, individually, only propantheline had significant improvement in leak frequency (p=0.039), and neither had significant changes in the other parameters
• Side effects included:
  • Increased thirst and dryness of mouth following intravesical oxybutynin in 2 patients.

Singh & Thomas 1995
UK
Downs & Black score=19
Pre-Post
N=6

Population: Mean age = 36yrs; Gender: males = 6.
Treatment: Oxybutynin Hydrochloride (10 mg) was instilled through the urethral catheter and left in the bladder for 60 minutes.
Outcome Measures: Maximum detrusor pressure, peak flow rate. Video urodynamic assessment was conducted before and after oxybutynin instillation.

• No significant difference was seen before and after oxybutynin instillation in:
  • Maximum detrusor pressure (p=0.2).
  • Peak flow rate (p=0.54).
• Urinary residue did not increase after oxybutynin instillation.

Vaidyananthan et al. 1998
England
Downs & Black score=10
Pre-post
N=7

Population: SCI; Age=22-69; Level=C6-T12; Time post-injury=6-38 years.
Treatment: IC 5-6 times a day alone first then with intra-vesical instillation of oxybutynin (5 mg in 30 ml) 1-3 times a day for 14 to 30 months in individuals originally managed by condom catheterization.
Outcome Measures: Customized scales of urinary continence, sexuality, quality of life and monitoring of side effects.

• No group results reported.
• All subjects showed  continence with IC and much moreso with oxybutynin added.
• 6/7 subjects reported  sexuality with IC and all subjects had even much higher ratings with oxybutynin added.
• Mixed results with quality of life with IC but consistently  quality of life when added oxybutynin.
• ↓ UTIs with IC and oxybutynin.